Health and Healthcare
Johnson & Johnson Offers a Strong Start to Earnings Season
Published:
Last Updated:
When Johnson & Johnson (NYSE: JNJ) reported its most recent quarterly results before the markets opened on Tuesday, the pharmaceutical giant said it had $2.12 in earnings per share (EPS) and $20.73 billion in revenue for its third quarter. The consensus estimates had called for $2.01 in EPS and $20.07 billion in revenue. In the same period of last year, it posted EPS of $2.05 on $20.35 billion in revenue.
Consumer worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 1.3% driven by Neutrogena beauty products and over-the-counter products, including Tylenol analgesics, international upper respiratory products and digestive health products, partially offset by lower sales of baby care products due to prior year U.S. relaunch activities.
Pharmaceutical worldwide operational sales grew 6.4%, driven by strong performance across its portfolio.
Worldwide Medical Devices operational sales, excluding the net impact of acquisitions and divestitures, grew 5.3%, driven by the growth of electrophysiology products in the Interventional Solutions business, Acuvue contact lenses in the Vision business, international energy products in the Advanced Surgery business, wound closure products in the General Surgery business and trauma products in the Orthopaedics business.
In terms of guidance, Johnson & Johnson expects to see full-year EPS in the range of $8.62 to $8.67 and sales up about 4.5% to 5.0%. Consensus estimates call for $8.60 in EPS and $81.48 billion in revenue for 2019.
Alex Gorsky, board chair and chief executive, commented:
Our third-quarter results represent strong performance, driven by competitive underlying growth in Pharmaceuticals and Medical Devices, as well as continued optimization in our Consumer business. As we look ahead, we remain confident in the strength of our broad-based business model, which is fueled by our disciplined portfolio management, focus on transformational innovation and dedicated employees around the world who position us for success today and well into the future.
Shares of Johnson & Johnson traded up 2% to $133.36 Tuesday morning, in a 52-week range of $121.00 to $148.99. The consensus price target is $149.17.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
